FJ Labs is a stage-agnostic investment firm that focuses on marketplaces and consumer-facing startups. Their investments are seed and series A. The investment range of the company is $50,000 to $5,000,000. It invests in Alibaba Group, Beepi, BrightRoll, Betterment, Adore Me, and Earnest.

FJ Labs

SALT Fund

We invest in great companies in the pre-seed and seed stages.

Yes VC

ICLUB Global is an international network of private investors in startups. Founded by TA Ventures, the community allows you to invest together in technological and high-growth companies of Europe and North America. Today the club has over 500 members, with offices in Ukraine, the UK, Switzerland, Monaco, Poland, Kazakhstan, and Cyprus. Since 2018 we have taken part in more than 60 deals. The amount invested exceeded $30 million, while the income from the exits approached a tangible $10 million. Participation in the club makes it possible for newcomers to enter the world of venture business and invest in startups in an accessible and understandable manner. Investors are offered only deals that TA Ventures has personally financed, significantly reducing the risk of building their portfolio.

ICLUB VC

Future Ventures is a financial services platform with a focus on disruptive technology companies such as commercial space exploration, deep learning, quantum computing, robotics, AI, blockchain, sustainable transportation, synthetic biology and clean meat. As venture capitalists, the founders of Future Ventures have led founding investments in several companies that had successful IPOs and others that were acquired for over $16 billion in aggregate. Some of our early VC investments include Memphis Meats, Mythic, Nervana, Planet, Rethink Robotics, Skype, SpaceX, Tesla and Zoox. Current board seats include SpaceX, Tesla, and D-Wave.

Future Ventures

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investment strategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Lux Capital

TA Ventures is a network-driven VC firm investing in early-stage tech startups shaping the industries of tomorrow, primarily across Europe and North America. Our typical initial check for Pre-Seed and Seed companies is $100-250k. TA Ventures also provides follow-on investments. We offer speed of execution, proactive support, and access to a broad international network. Drawing upon our network, we support our portfolio companies by proactively soliciting large, growth-minded co-investors in subsequent rounds. We utilize our industry knowledge and network to give portfolio companies and partner VCs access to highly skilled and cost-effective R&D outsourcing teams in Central and Eastern Europe.

TA Ventures

Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.

Bold Capital Partners

Plum Alley is a venture firm investing in early stage, high growth technology and healthcare companies with at least one woman founder from the STEM fields. Plum Alley invests in advanced technologies and medical breakthroughs, disrupting huge markets and driving exponential value for people, the planet, markets, and the economy. The firm invests both via the Plum Alley Venture Fund I LP as well as through Plum Alley Syndicates. As of April 30th, 2021, Plum Alley has invested over $35M across 24 companies.

Plum Alley

Overwater Ventures is an investment firm.

Overwater Ventures

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. The company invests in companies with promising technologies and products.

RA Capital Management

Two Sigma Ventures is an early-stage venture capital fund based in New York City investing capital and expertise in entrepreneurs leveraging data and computing to create the future. In partnership with our parent company, Two Sigma Investments, we provide entrepreneurs access to a proprietary network of experts and startup resources to give them a competitive edge.

Two Sigma Ventures

Insight Partners is a global software investor that partners with growth-stage technology and software companies. Insight has a deep focus in Fintech, Cybersecurity, AI/ML, DevOps, and Healthcare sectors. Across their people and their portfolio, they encourage a culture around a core belief growth equals opportunity. As of December 31, 2022, the firm has over $75B in regulatory assets under management. Insight Partners has invested in more than 750 companies worldwide and has seen over 55 portfolio companies achieve an IPO.

Insight Partners

Arcadian Investment Partners (“Arcadian”) is an investment firm focused on direct investments in growing middle-market companies. Our mission is to build industry-leading middle-market companies that generate sustainable profits for the long-term. Arcadian takes majority investment positions in portfolio companies, who then benefit from having a long-term operational and capital partner that supports management’s expansion strategy. Arcadian is backed by investors who have been long-term partners in past investments in the US, Europe, and Africa.

Arcadian Investment Partners

Myelin VC is Investing in companies that accelerate collective intelligence.

Myelin VC

Ingeborg Investments is a venture capital firm that invests in women-led enterprises at the seed, early-stage, and series B levels. They admire innovation that empowers and improves parenting, careers, financial security, women's health, and overall quality of life.

Ingeborg Investments

Gameto

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones.  Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases.  Gameto's first program, Fertilo,  is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo,  and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

Gameto, founded in 2020, develops treatment solutions to improve women's reproductive health, including egg freezing, infertility, and diseases of the reproductive years, as well as menopause and other conditions that occur subsequently.

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Gameto lands ARPA-H funding to combat menopause with cell therapy

Gameto, founded in 2020, develops treatment solutions to improve women's reproductive health, including egg freezing, infertility, and diseases of the reproductive years, as well as menopause and other conditions that occur subsequently.Gameto is currently engaged in developing an IVF and egg-freezing process, called Fertilo.Fertilo is an iPSC-derived solution that seeks to mature oocytes outside of the body, reducing the hormonal burden on patients undergoing fertility treatments. The use of the Clinical Seed iPSCs in Fertilo is expected to make IVF and egg freezing safer, easier, and more accessible, offering improved fertility care for women.Key customers and partnershipsIn October 2023, Japan-based biotechnology company, REPROCELL granted Gameto a non-exclusive right to use its StemRNA Clinical Seed-induced Pluripotent Stem Cells (iPSCs) for the development and commercialization of Fertilo.Funding and financialsThe company had its latest funding round in September 2022, a venture-series round.

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

<div>
 
 Gameto, a provider of egg freezing and storage services, has successfully raised USD 33 million in a Series B funding round that witnessed over-subscription. This funding round was co-led by Two Sigma Ventures and RA Capital and saw participation from Insight Partners, Future Ventures, and BOLD Capital Partners. With this new funding, Gameto's total funding has reached USD 73 million.
 The funding is expected to be used for supporting the clinical development of Fertilo, the company’s latest in vitro maturation (IVM) solution, within the US. Furthermore, the funds will also be directed towards commercial launches in Australia and Latin America, where it is already in clinical use. Fertilo is a revolutionary solution that includes engineered ovarian support cells (OSCs) capable of maturing eggs outside the human body.
 
</div>

Gameto

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless